pharmaceutical development

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company dedicated to tackling the global nicotine dependence epidemic by advancing cytisinicline as a treatment for smoking and vaping cessation. The company is focused on addressing the global smoking health epidemic through the development and commercialization of cytisinicline, which, if approved, has the potential to become the first new FDA-approved treatment option in 20 years.

clinical trialscommercialization

of page ANTIBIOTIC RESISTANCEis creating an era in which common infections that used to be easily treated with penicillin and other antibiotics now routinely kill people.Atterx Biotherapeutics is introducing novel solutions to prevent and treat antibiotic-resistant infections.GN-4474: Gram Negative Bacterial Infections LEARN MOREC-1205: Catheter Associated Urinary Tract Infections LEARN MOREAnnual deaths due to antimicrobial resistance expected to rise dramatically by 2050.ABOUT ATTERX BIOTHERAPEUTICSAntibiotics are among the most commonly prescribed drugs, and have saved millions of lives since they were introduced to patients many decades ago. However, they are frequently overused and can be improperly prescribed. As a result, bacteria that were once easy to treat with antibiotics are now changing and becoming resistant to them. ​ continue reading...LATEST NEWSMay 1, 2025Atterx.

bacterial conjugation technologybacterial interference technologyclinical trials

Bausch Health Companies Inc. is a global, diversified pharmaceutical company whose mission is to improve people's lives with its pharmaceutical products. It develops, manufactures and markets branded and generic pharmaceuticals and over-the-counter products in more than 90 countries and regions, with focus areas including gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.

clinical trialsmanufacturingmarketingresearch and development

Captura Biopharma is a Little Rock, AR company founded in 2019 by Michael Geranen and Anthony Soscia based on research at the University of North Carolina. It is developing C2E2, an oral solution designed to bind and eliminate radioactive heavy metals and radionuclides from the body, intended as a mass casualty decorporation agent for radiation exposure. Secondary indications include heavy metal toxicity such as lead poisoning and potentially Gadolinium toxicity.

oral drug formulation

Coeurative, Inc. is developing a pharmaceutical management strategy for Coronary Artery Disease and its main symptom complex, Angina Pectoris. The company is harnessing a cellular response to a deficiency in blood and oxygen to open a coronary artery more effectively and selectively than currently available vasodilators, with a focus on patients with INOCA and refractory angina pectoris. Its lead compound CR-0305 uses a proprietary dual-mechanism approach, with IND-enabling studies underway and Phase 1 trials planned for 2028.

IND-enabling studies

Evofem Biosciences is a women's sexual and reproductive healthcare company whose mission is to empower women by providing products that give them control and flexibility. Its FDA-approved PHEXXI (lactic acid, citric acid and potassium bitartrate) vaginal gel, launched in 2020, is a first-in-class hormone-free, on-demand prescription contraception. The company also acquired SOLOSEC (secnidazole) 2 g oral granules, an oral antibiotic approved to treat bacterial vaginosis and trichomoniasis with one dose.

commercialization of prescription productswomen's sexual and reproductive healthcare

Fitabeo Therapeutics is a pharmaceutical company that develops medicines bridging the gap between medical science and unmet patient needs, using novel technologies to alleviate drug therapy issues across clinical conditions. It holds patents in the US and EU for its SpherionexT technology and has partnered with TSP Therapeutics to develop cancer treatments.

drug delivery technology

ForCast Orthopedics is a development-stage company focused on modernizing care for complex orthopedic infections, pioneering targeted antibiotic therapy and localized drug delivery for periprosthetic joint infection (PJI) following joint replacement surgery. Its proprietary platform automates a treatment method demonstrated in clinical research to achieve superior patient outcomes versus the standard of care.

localized treatment of PJIproduct developmenttargeted drug delivery